Cholinergic markers in elderly patients with early signs of Alzheimer disease

JAMA

Volumn 281, Issue 15, 1999, Pages 1401-1406

  Davis, Kenneth L ^a   Mohs, Richard C ^a   Marin, Deborah ^a   Purohit, Dushyant P ^a   Perl, Daniel P ^a   Lantz, Melinda ^b   Austin, Gregory ^a   Haroutunian, Vahram ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Jewish Home and Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CHOLINERGIC ACTIVITY; CLINICAL FEATURE; COGNITION; DEMENTIA; DISEASE MARKER; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0033591017     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.15.1401     Document Type: Article

References (30)

1. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet. 1977;1:189.
2. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1975; 2:1403.
3. Bowen DM, Benton JS, Spillane JA, Smith CC, Allen SJ. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci. 1982;57:191-202.
4. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;2:1457-1459.
5. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem. 1995;64:749-760.
6. Santucci AC, Haroutunian V, Tsuboyama GK, Kanof PD, Davis KL. Therapeutics of Alzheimer's disease for clinical and pre-clinical issues. In: Iqbal K, Wisniewski HM, Winblad B, eds. Progressin Clinical and Biological Research. New York, NY: Alan R Liss Inc; 1989: 1111-1120.
7. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with AD. Am J Psychiatry. 1985;142:28-33.
8. Davis KL, Thai LT, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. W Engl J Med. 1992; 327:1253-1259.
9. DeKosky ST, Harbaugh RE, Schmitt FA, et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical neuropathological, and cognitive correlations: Intraventricular Bethanecol Study Group. Ann Neurol. 1992;32:625-632.
10. Martin EM, Wilson RS, Penn RS, Fox JH, Clasen RA, Savoy RN. Cortical biopsy results in Alzheimer's disease: correlation with cognitive deficits. Neurology. 1987;37:1201-1204.
11. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychol. 1982;140:566-572.
12. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Arch Neurol. 1993; 43:2412-2414.
13. Folstein M, Folstein S, McHugh P. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
14. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141: 1356-1364.
15. Haroutunian V, Perl DP, Purohit DP, et al. Regional distribution of neuritic plaques in nondemented elderly and cases of very mild Alzheimer's disease. Arch Neurol. 1998;55:1185-1191.
16. Haroutunian V, Purohit DP, Perl DP, et al. Neurofibrillary tangles in nondemented elderly and very mild Alzheimer's disease. Arch Neurol. In press.
17. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
18. Damasio H, Damasio AR, eds. Lesion Analysis in Neuropsychology. New York, NY: Oxford University Press; 1989:184-221.
19. Haroutunian V, Davidson M, Kanof PD, et al. Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994;12:137-144.
20. Fonnum F. A rapid radiochemical method of determination of choline acetyltransferase. J Neurochem. 1975;24:407-409.
21. Johnson CD, Russell RL. A rapid, simple radiometric assay for acetylcholinesterase, suitable for multiple determinations. Anal Biochem. 1975;64:229-232.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
23. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985;42:1097-1105.
24. Li G, Silverman JM, Smith CJ, et al. Age at onset and familial risk in Alzheimer's disease. Am J Psychiatry. 1995;152:424-430.
25. Silverman JM, Li G, Zaccario ML, et al. Patterns of risk in first-degree relatives of patents with Alzheimer's disease. Arch Gen Psychiatry. 1994;51:577-588.
26. Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS. Physostigmine: improvement of long-term memory processes in normal humans. Science. 1978;201:272-274.
27. Farlow MR, Brashear H, Hui S, Schneider LS, Unverzagt F, for the Tacrine Study Group. The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease. In: Iqbal K, Mortimer JA, Winblad B, Wisnieski H, eds. Research Advances in Alzheimer's Disease and Related Disorders. New York, NY: John Wiley & Sons Inc; 1995:284-292.
28. Bartus RT, Pontecorvo MJ, Flicker C, Dean RL, Figueiredo JC. Behavioral recovery following bilateral lesions of the nucleus basalis does not occur spontaneously. Pharmacol Biochem Behav. 1986;24:1287-1292.
29. Wenk GL, Olton DS. Recovery of neocortical choline acetyltransferase activity following ibotenic acid injection into the nucleus basalis of Meynert in rats. Brain Res. 1984;293:184-186.
30. Cotman C, Schieff S. Compensatory synapse growth in aged animals after neuronal death. Mech Ageing Dev. 1979;9:103-117.